Cartesian Therapeutics (RNAC) Asset Utilization Ratio: 2016-2025
Historic Asset Utilization Ratio for Cartesian Therapeutics (RNAC) over the last 9 years, with Sep 2025 value amounting to 0.00.
- Cartesian Therapeutics' Asset Utilization Ratio fell 97.60% to 0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.00, marking a year-over-year decrease of 97.60%. This contributed to the annual value of 0.11 for FY2024, which is 4.78% down from last year.
- Per Cartesian Therapeutics' latest filing, its Asset Utilization Ratio stood at 0.00 for Q3 2025, which was up 11.43% from 0.00 recorded in Q2 2025.
- Over the past 5 years, Cartesian Therapeutics' Asset Utilization Ratio peaked at 0.76 during Q2 2022, and registered a low of 0.00 during Q2 2025.
- Over the past 3 years, Cartesian Therapeutics' median Asset Utilization Ratio value was 0.12 (recorded in 2024), while the average stood at 0.16.
- Per our database at Business Quant, Cartesian Therapeutics' Asset Utilization Ratio skyrocketed by 459.09% in 2021 and then tumbled by 98.40% in 2025.
- Over the past 5 years, Cartesian Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.52 in 2021, then increased by 23.74% to 0.64 in 2022, then slumped by 80.35% to 0.13 in 2023, then slumped by 30.91% to 0.09 in 2024, then tumbled by 97.60% to 0.00 in 2025.
- Its last three reported values are 0.00 in Q3 2025, 0.00 for Q2 2025, and 0.08 during Q1 2025.